The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Rafael Rosell

Catalan Institue of Oncology

Hospital Germans Trias i Pujol

Badalona

Catalonia

Spain

[email]@ico.scs.es

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Catalan Institue of Oncology, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain. 2005 - 2010
  • Hospital Germans Trias i Pujol, Catalan Institute of Oncology, Medical Oncology Service, Ctra Canyet, Spain. 2010
  • Catalan Institute of Oncology, Badalona, Spain. 2006 - 2009
  • Medical Oncology Service, Scientific Director of Oncology Research Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Ctra Canyet, Spain. 2007

References

  1. Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer. Rosell, R., Viteri, S., Molina, M.A., Benlloch, S., Taron, M. Curr. Opin. Oncol (2010) [Pubmed]
  2. Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer. Rosell, R., Moran, T., Viteri, S., Carcereny, E., Gasco, A., Quiroga, V., Wei, J., Camps, C., Massuti, B. Expert. Opin. Pharmacother (2010) [Pubmed]
  3. Predictive biomarkers in the management of EGFR mutant lung cancer. Rosell, R., Moran, T., Cardenal, F., Porta, R., Viteri, S., Molina, M.A., Benlloch, S., Taron, M. Ann. N. Y. Acad. Sci. (2010) [Pubmed]
  4. Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain. Rosell, R., Morán, T., Carcereny, E., Quiroga, V., Molina, M.A., Costa, C., Benlloch, S., Tarón, M. Clin. Transl. Oncol (2010) [Pubmed]
  5. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. Rosell, R., Perez-Roca, L., Sanchez, J.J., Cobo, M., Moran, T., Chaib, I., Provencio, M., Domine, M., Sala, M.A., Jimenez, U., Diz, P., Barneto, I., Macias, J.A., de Las Peñas, R., Catot, S., Isla, D., Sanchez, J.M., Ibeas, R., Lopez-Vivanco, G., Oramas, J., Mendez, P., Reguart, N., Blanco, R., Taron, M. PLoS. ONE (2009) [Pubmed]
  6. IL-6/gp130/STAT3 signaling axis in cancer and the presence of in-frame gp130 somatic deletions in inflammatory hepatocellular tumors. Rosell, R., Bertran-Alamillo, J., Molina, M.A., Taron, M. Future. Oncol (2009) [Pubmed]
  7. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Rosell, R., Robinet, G., Szczesna, A., Ramlau, R., Constenla, M., Mennecier, B.C., Pfeifer, W., O'Byrne, K.J., Welte, T., Kolb, R., Pirker, R., Chemaissani, A., Perol, M., Ranson, M.R., Ellis, P.A., Pilz, K., Reck, M. Ann. Oncol. (2008) [Pubmed]
  8. Translational research in glioblastoma multiforme: molecular criteria for patient selection. Rosell, R., de Las Peñas, R., Balaña, C., Santarpia, M., Salazar, F., de Aguirre, I., Reguart, N., Villa, S., Wei, J., Ramirez, J.L., Molina, M.A., Ramon y Cajal, S., Jablons, D., Taron, M. Future. Oncol (2008) [Pubmed]
  9. How could pharmacogenomics help improve patient survival? Rosell, R., Felip, E., Paz-Ares, L. Lung. Cancer (2007) [Pubmed]
  10. Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors. Rosell, R., Taron, M., Sanchez, J.J., Paz-Ares, L. Future. Oncol (2007) [Pubmed]
  11. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. Rosell, R., Skrzypski, M., Jassem, E., Taron, M., Bartolucci, R., Sanchez, J.J., Mendez, P., Chaib, I., Perez-Roca, L., Szymanowska, A., Rzyman, W., Puma, F., Kobierska-Gulida, G., Farabi, R., Jassem, J. PLoS. ONE (2007) [Pubmed]
  12. Platinum resistance related to a functional NER pathway. Rosell, R., Mendez, P., Isla, D., Taron, M. J. Thorac. Oncol (2007) [Pubmed]
  13. Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going. Rosell, R., Cuello, M., Cecere, F., Santarpia, M., Reguart, N., Felip, E., Taron, M. Curr. Opin. Oncol (2006) [Pubmed]
  14. Future directions in the second-line treatment of non-small cell lung cancer. Rosell, R., Cecere, F., Cognetti, F., Cuello, M., Sanchez, J.M., Taron, M., Reguart, N., Jablons, D. Semin. Oncol. (2006) [Pubmed]
  15. Predicting the outcome of chemotherapy for lung cancer. Rosell, R., Cecere, F., Santarpia, M., Reguart, N., Taron, M. Curr. Opin. Pharmacol (2006) [Pubmed]
  16. Pharmacogenomics and gemcitabine. Rosell, R., Cobo, M., Isla, D., Camps, C., Massuti, B. Ann. Oncol. (2006) [Pubmed]
  17. Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway. Rosell, R., Taron, M., Reguart, N., Isla, D., Moran, T. Clin. Cancer Res. (2006) [Pubmed]
  18. The place of targeted therapies in the management of non-small cell bronchial carcinoma. Molecular markers as predictors of tumor response and survival in lung cancer. Rosell, R., Moran, T., Fernanda Salazar, M., Mendez, P., De Aguirre, I., Ramirez, J.L., Isla, D., Cobo, M., Camps, C., Lopez-Vivanco, G., Alberola, V., Taron, M. Rev. Mal. Respir (2006) [Pubmed]
  19. Applications of genomics in NSCLC. Rosell, R., Cobo, M., Isla, D., Sanchez, J.M., Taron, M., Altavilla, G., Santarpia, M., Moran, T., Catot, S., Etxaniz, O. Lung. Cancer (2005) [Pubmed]
 
WikiGenes - Universities